It is hypothesised that there is a difference between the uptake of a radioactive substance (\[18F\]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
Single site, eligible subjects enrolled in order of presentation.
Study Type
OBSERVATIONAL
Enrollment
20
Medical imaging assessment
Pfizer Investigational Site
St Louis, Missouri, United States
Uptake of FDG (Ki) at <1 and 4 weeks
Time frame: <1 and 4 weeks
BODE Index (Screening)
Time frame: Screening
Chronic Respiratory Questionnaire (1week and 4 weeks)
Time frame: <1 week and 4 weeks
Emphysema index (chest CT emphysema score) (Screening)
Time frame: Screening
Airway wall area (as % total airway cross-sectional area) (chest CT assessment, see Appendix 3 for details) (1 week and 4 weeks)
Time frame: <1 week and 4 weeks
Clinical COPD Questionnaire (Screening 1 week and 4 weeks)
Time frame: Screening <1 week and 4 weeks
COPD GOLD Stage (screening)
Time frame: Screening
Lung function indices (FEV1, FVC, FEV1/FVC, DLco) and lung volumes (TLC, IC, RV) (Screening 1 week and 4 weeks)
Time frame: screening, <1 week and 4 weeks
St. George's Respiratory Questionnaire (screening)
Time frame: Screening
Smoking history (screening)
Time frame: Screening
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.